| Issue Date | Title | Author(s) |
| 14-May-2024 | Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy | Jia, Jia; Mao, Lili; Lin, Jing; Li, Wenyu; Yuan, Pei; Guo, Lei; Dai, Jie; Li, Caili; Bai, Xue; Li, Zhongwu; Chen, Yu; Guo, Jun; Ying, Jianming; Si, Lu |
| 2017 | Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China | Shi, Yuankai; Jia, Bo; Xu, Wei; Li, Wenyu; Liu, Ting; Liu, Peng; Zhao, Weili; Zhang, Huilai; Sun, Xiuhua; Yang, Haiyan; Zhang, Xi; Jin, Jie; Jin, Zhengming; Li, Zhiming; Qiu, Lugui; Dong, Mei; Huang, Xiaobing; Luo, Yi; Wang, Xiaodong; Wang, Xin; Wu, Jianqiu; Xu, Jingyan; Yi, Pingyong; Zhou, Jianfeng; He, Hongming; Liu, Lin; Shen, Jianzhen; Tang, Xiaoqiong; Wang, Jinghua; Yang, Jianmin; Zeng, Qingshu; Zhang, Zhihui; Cai, Zhen; Chen, Xiequn; Ding, Kaiyang; Hou, Ming; Huang, Huiqiang; Li, Xiaoling; Liang, Rong; Liu, Qifa; Song, Yuqin; Su, Hang; Gao, Y |
| 15-Nov-2022 | Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China | Lin, Zhijuan; Zha, Jie; Yi, Shuhua; Li, Zhifeng; Ping, Lingyan; He, Xiaohua; Fan, Liyuan; Yu, Haifeng; Zheng, Zhong; Xu, Wei; Chen, Feili; Xie, Ying; Chen, Bi-yun; Zhang, Huilai; Wang, Li; Ding, Kaiyang; Li, Wenyu; Yang, Haiyan; Zhao, Weili; Qiu, Lugui; Li, Zhiming; Song, Yuqin; Xu, Bing |
| 23-Aug-2021 | Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China | Zha, Jie; Fan, Liyuan; Yi, Shuhua; Yu, Haifeng; Zheng, Zhong; Xu, Wei; Deng, Manman; Lin, Zhijuan; Li, Zhifeng; Ping, Lingyan; He, Xiaohua; Chen, Feili; Xie, Ying; Chen, Biyun; Zhang, Huilai; Wang, Li; Ding, Kaiyang; Li, Wenyu; Yang, Haiyan; Zhao, Weili; Qiu, Lugui; Li, Zhiming; Song, Yuqin; Xu, Bing |
| 15-Nov-2022 | Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China | Song, Yuqin; Ying, Zhitao; Yang, Haiyan; Guo, Ye; Li, Wenyu; Zou, Dehui; Wu, Jianqiu; Tian, Alex; Huang, Tony; Zhou, Zisong; Ma, Meilin; Yang, Su; Qin, Yun; Zhu, Jun |
| 2-Nov-2023 | Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8) | Song, Yuqin; Malpica, Luis; Cai, Qingqing; Zhao, Weili; Zhou, Keshu; Wu, Jianqiu; Zhang, Huilai; Ding, Kaiyang; Liu, Yao; Li, Zengjun; Mehta-Shah, Neha; Zhang, Liling; Zheng, Meifang; Jin, Jie; Yang, Haiyan; Shuang, Yuerong; Yoon, Dok Hyun; Gao, Sujun; Li, Wenyu; Zhai, Zhimin; Zou, Liqun; Xi, Yaming; Koh, Youngil; Li, Fei; Prince, Miles; Zhou, Hui; Lin, Lie; Liu, Hui; Yang, Zhenfan; Kim, Won Seog; Zhu, Jun |
| 2-Nov-2023 | Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Lin, Ningjing; Sun, Xiuhua; Zhou, Hui; Zou, Liqun; Zhou, Keshu; Liu, Lihong; Yang, Haiyan; Hu, Kai; Cai, Qingqing; Liu, Yao; Jin, Jie; Zhang, Liling; Li, Wenyu; Guo, Ye; Yang, Wei; Luo, Feng; Li, Yanyan; Zhang, Mengqi; Lu, Feinan; Song, Yuqin; Zhu, Jun |
| 4-Nov-2021 | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China | Liu, Weiping; Zhao, Donglu; Liu, Ting; Niu, Ting; Song, Yongping; Xu, Wei; Jin, Jie; Cai, Qingqing; Huang, Huiqiang; Li, Zhiming; Hou, Ming; Zhang, Huilai; Zhou, Jianfeng; Hu, Jianda; Shen, Jianzhen; Shi, Yuankai; Yang, Yu; Zhang, Liling; Zhao, Weili; Ding, Kaiyang; Qiu, Lugui; Tan, Huo; Zhang, Zhihui; Liu, Lihong; Wang, Jinghua; Xu, Bing; Zhou, Hui; Gao, Guangxun; Xue, Hongwei; Bai, Ou; Feng, Ru; Huang, Xiaobing; Yang, Haiyan; Yan, Xiaojing; Zeng, Qingshu; Liu, Peng; Li, Wenyu; Mao, Min; Su, Hang; Wang, Xin; Xu, Jingyan; Zhou, Daobin; Zhang, Hongyu; Ma, Jun; Shen, Zhixiang; Zhu, Jun |
| 2023 | Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study | Deng, Lijuan; Li, Zhiming; Zhang, Huilai; Huang, Haiwen; Hu, Jianda; Liu, Lihong; Liu, Ting; Jin, Jie; Zhu, Zunmin; Li, Wenyu; Huang, Zhenqian; Huang, Wenrong; Zhou, Keshu; Yang, Haiyan; Zhang, Mingzhi; Ding, Kaiyang; Zhou, Hui; Hu, Yu; Shuang, Yuerong; Cao, Junning; Gao, Sujun; Li, Dengju; Sun, Zimin; Zhang, Qingyuan; Yi, Shuhua; Ji, Chunyan; Zhang, Liansheng; Hou, Cheng; Du, Yue; Wang, Weige; Zhao, Renbin; Song, Yuqin; Zhu, Jun |
| Jul-2024 | Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors | Song, Yuqin; Cao, Junning; Zhang, Qingyuan; Li, Caixia; Qiu, Lugui; Qi, Junyuan; Zhang, Huilai; Li, Wenyu; Liu, Lihong; Jing, Hongmei; Zhou, Keshu; Zhang, Weijing; Zhang, Liling; Li, Daqi; Zou, Liqun; Yang, Haiyan; Qian, Wenbin; Zhou, Hui; Hu, Jianda; Yin, Hongyan; Fu, Sisi; Fan, Songhua; Xu, Qian; Wang, Jian; Jia, Xiaoyun; Dai, Guangxiu; Su, Weiguo; Zhu, Jun |
| 15-Nov-2022 | Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAbTrap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL) | Shi, Yuankai; Song, Yongping; Zhang, Mingzhi; Jing, Hongmei; Wang, Zhen; Li, Zhiming; Qi, Junyuan; Li, Fei; Li, Wenyu; Yang, Jianliang; Gao, Siman; Ma, Huizi; He, Heming; Lu, Qiying; Tian, Wenzhi |
